Clinical trials: Chronic HCV Infection
Hepatitis C, Chronic
First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC)…
- Trial name
- NCT01590407
- Testing
- ALS-002200
- Where
- 4 sites in France, Moldova and 1 more
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Chronic Hepatitis C
A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)
This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy…
- Trial name
- NCT01157104
- Testing
- IDX320, IDX184
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients
The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million).
- Trial name
- NCT03687229
- Testing
- A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis C, Chronic Hepatitis C
Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C
The Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C) compares the effectiveness of the birth cohort HCV screening strategy with the current risk-based screening approach to detect previous…
- Trial name
- Best-C (NCT02123212)
- Testing
- Mailer, In-person recruitment, EHR Alert
- Where
- 3 sites in United States
- Volunteers
- 29,607 people, healthy volunteers welcome
- Sponsor
- National Opinion Research Center
Chronic Hepatitis c
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China
The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
- Trial name
- NCT03430830
- Testing
- Ravidasvir 50mg, Ravidasvir 200mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Chronic Hepatitis C, Renal Impairment
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of combination oral therapy for hepatitis C virus (HCV).
- Trial name
- NCT01937975
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Hepatitis C
Study of AT-527 in Healthy and HCV-Infected Subjects
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT03219957
- Testing
- AT-527
- Where
- 2 sites in Belgium, Moldova
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C, Breast Cancer
Hepatitis C Screening Paired With Mammography
In France, a breast cancer screening is organized since 2004 for women aged 50-74. On the other hand, even though the seroprevalence of hepatitis C in the general French population is less than 1%, it is estimated that more than…
- Trial name
- Mammo'C (NCT05067374)
- Where
- 4 sites in France
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Hepatitis C, Chronic
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.
- Trial name
- NCT01508156
- Testing
- IDX719
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection…
- Trial name
- NCT04943588
- Testing
- HCV RNA (PCR), HCV Antibody test (Point of care), AST/ALT and platelets measurement
- Where
- Pakistan
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Hepatitis C, Chronic, Disease Progression
Prospective Observational Study of Disease Progression in Chronic Hepatitis C
The purpose of this study is to determine the progression of chronic hepatitis C patients infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease progression in chronic hepatitis C.
- Conditions
- Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis
- Trial name
- NCT02011932
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Beijing YouAn Hospital
Hepatitis C
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
The purpose of this study is to assess the safety and tolerability of TMC647055 both after increasing single oral doses from 100 mg up to maximum 3000 mg in fed conditions, and after multiple oral doses in fed conditions at…
- Trial name
- NCT01202825
- Testing
- TMC647055, TMC435
- Where
- Belgium
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis C
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.
- Trial name
- NCT00960479
- Testing
- Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.), Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Sandoz
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Hepatitis C, Chronic
Drug-drug Interaction of BI 201335 and Microgynon
This study will investigate possible effect of multiple oral doses of BI 201335 on the steady state pharmacokinetics of ethinylestradiol and levonogestrel
- Trial name
- NCT01570244
- Testing
- levonorgestrel, Ethinylestradiol, BI 201335
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Failure, Hepatic Impairment
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
The objective was to determine if hepatitis C virus (HCV) infection or mild to severe hepatic impairment (Child-Pugh Classes A, B, and C) altered the PK of buprenorphine, norbuprenorphine, or naloxone.
- Conditions
- Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
- Trial name
- NCT01846455
- Testing
- 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Hepatitis C, Chronic, Healthy Volunteer
A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo controlled, 3 part study will assess the safety, tolerability and pharmacokinetics of RO5303253 in healthy volunteers and patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01181024
- Testing
- RO5303253
- Where
- New Zealand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche